✦ LIBER ✦

Parkinson’s disease in patients and obligate carriers of Gaucher disease

✍ Scribed by Joanna G. Becker; Gregory M. Pastores; Alessandro Di Rocco; Marissa Ferraris; Jerome J. Graber; Swati Sathe

Book ID: 119343097
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 109 KB
Volume: 19
Category: Article
ISSN: 1353-8020
DOI: 10.1016/j.parkreldis.2012.06.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Parkinson disease penetrance in patients

Parkinson disease penetrance in patients with Gaucher disease and in glucocerebrosidase mutation carriers

✍ Dinur, Tama; Quinn, Timothy; Sakanaka, Karina; Levy, Oren; Marder, Karen S.; Wat 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Phenotype in patients with Gaucher disea

Phenotype in patients with Gaucher disease and Parkinson disease

✍ Chetrit, Eli Ben; Alcalay, Roy N.; Steiner-Birmanns, Bettina; Altarescu, Gheona; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 261 KB

O.036 Gaucher's disease and Parkinson's

O.036 Gaucher's disease and Parkinson's disease

✍ N. Wood 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 57 KB

α-synuclein polymorphisms in patients wi

α-synuclein polymorphisms in patients with Gaucher disease and Parkinson disease

✍ Altarescu, Gheona; Ioscovich, Daniel; Alcalay, Roy; Zimran, Ari; Elstein, Debora 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Biochemical properties of β-glucosidase

Biochemical properties of β-glucosidase in leukocytes from patients and obligated heterozygotes for Gaucher disease carriers

✍ Kristiane Michelin; Alessandro Wajner; Hugo Bock; Ângela Fachel; Roberto Rosenbe 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 288 KB

Hyposmia and cognitive impairment in Gau

Hyposmia and cognitive impairment in Gaucher disease patients and carriers

✍ Alisdair McNeill; Raquel Duran; Christos Proukakis; Jose Bras; Derralyn Hughes; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 852 KB

The objective of this study was to assess a cohort of Gaucher disease patients and their heterozygous carrier relatives for potential clinical signs of early neurodegeneration. Gaucher disease patients (n = 30), heterozygous glucocerebrosidase mutation carriers (n = 30), and mutation-negative contro